Press release
AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
New Real-World Evidence Highlights AMGEVITA® Utilization, Treatment Satisfaction and Persistence in European Patients New Data From First-in-Class Treatment
About this update from Amgen Inc.
[{"type":"text","content":"New Real-World Evidence Highlights AMGEVITA® Utilization, Treatment Satisfaction and Persistence in European Patients\nNew Data From First-in-Class Treatment TAVNEOS®, Evaluating Renal Function Among Adults Living With Severe Active ANCA-Associated Vasculitis\nTHOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022. \nAmong 25 abstracts, noteworthy presentations will include real-world evidence for AMGEVITA®* (adalimumab), underscoring treatment satisfaction and persistence in German patients with rheumatic diseases. Additional data will highlight utilization in European patients with moderate to severe rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.\nOther research highlights include data on TAVNEOS® (avacopan) in severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, notably an oral presentation on evaluation of recovery of renal function among patients with baseline estimated glomerular filtration rate (eGFR) at or below 20; renal function is impaired in the majority of people with the disease. Additionally, two real-world evidence posters report on the effects of Otezla® (apremilast) on cardiometabolic parameters in patients with psoriatic disease.\n\"Given the uptake of biosimilars, we are looking forward to presenting real-world evidence data from the experiences of patients using AMGEVITA, since it was approved in Europe four years ago,\" said David M. Reese, M.D., executive vice president of Research and Development at Amgen. \"The breadth of data being presented reflects our deep commitment to driving innovation in inflammatory diseases.\"\n*AMJEVITA™ outside the US is marketed as AMGEVITA. AMJEVITA is currently not available commercially and will not be commercially available in the United States until on or after January 31, 2023.\nAbstracts and Presentation Times:\nAMGEVITA® (adalimumab) Abstracts\nReal-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe Abstract #1387, Virtual Poster Session, Sunday, No...